bocunebart

News

Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.

News

Ibrance has become the first CDK4/6 inhibitor to be approved for a challenging subtype of breast cancer that is often resistant to current treatment.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.